Isn’t that Her-vaxx in combo with Key-vaxx? I believed that’s what achieved the 90% inhibition.
Imugene are just focusing on a partnership which is brilliant. If the market is after a PD-1 they went out and snatched some up.
If the potential for a partnership is more likely to eventuate with the PD-1 than they should move Her-vaxx to the background.
Ann: 2018 Bioshares Presentation, page-5
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.9¢ |
Change
0.005(9.26%) |
Mkt cap ! $433.6M | |||
| Open | High | Low | Value | Volume |
| 5.5¢ | 5.9¢ | 5.4¢ | $1.489M | 25.99M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 35252 | 5.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.0¢ | 1753430 | 24 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |